133 related articles for article (PubMed ID: 37309168)
1. Incidence of invasive fungal infections in patients with chronic lymphocytic leukemia receiving ibrutinib within the veteran's healthcare administration.
Walker C; Horowitz A; Nooruddin Z; Frei CR
J Oncol Pharm Pract; 2024 Jun; 30(4):673-677. PubMed ID: 37309168
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections.
Maffei R; Maccaferri M; Arletti L; Fiorcari S; Benatti S; Potenza L; Luppi M; Marasca R
Blood Rev; 2020 Mar; 40():100635. PubMed ID: 31699465
[TBL] [Abstract][Full Text] [Related]
3. Invasive fungal infection incidence and risk factors in patients receiving ibrutinib in real-life settings: A nationwide population-based cohort study.
Allouchery M; Brunet K; Tomowiak C; Singier A; Pambrun E; Pariente A; Bezin J; Pérault-Pochat MC; Salvo F
Mycoses; 2024 Jan; 67(1):e13676. PubMed ID: 37984556
[TBL] [Abstract][Full Text] [Related]
4. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
Huang Q; Borra S; Li J; Wang L; Shrestha S; Sundaram M; Janjan N
J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204
[TBL] [Abstract][Full Text] [Related]
5. Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factors.
Georgantopoulos P; Yang H; Norris LB; Bennett CL
Cancer Med; 2019 May; 8(5):2233-2240. PubMed ID: 30983123
[TBL] [Abstract][Full Text] [Related]
6. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
[TBL] [Abstract][Full Text] [Related]
7. Incidence of invasive fungal infections in patients with hematological malignancies receiving ibrutinib therapy in south-east Austria.
Egger M; Gornicec M; Wölfler A; Lembeck AL; Tinchon C; Maderdonner M; Prattes J
Med Mycol; 2022 Sep; 60(9):. PubMed ID: 36029283
[TBL] [Abstract][Full Text] [Related]
8. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
[TBL] [Abstract][Full Text] [Related]
9. Infectious complications among patients receiving ibrutinib for the treatment of hematological malignancies.
Tham K; Prelewicz S; deHoll S; Stephens DM; Gomez CA
Am J Health Syst Pharm; 2024 Feb; 81(4):112-119. PubMed ID: 37675967
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
[TBL] [Abstract][Full Text] [Related]
11. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
Archibald WJ; Rabe KG; Kabat BF; Herrmann J; Ding W; Kay NE; Kenderian SS; Muchtar E; Leis JF; Wang Y; Chanan-Khan AA; Schwager SM; Koehler AB; Fonder AL; Slager SL; Shanafelt TD; Call TG; Parikh SA
Ann Hematol; 2021 Jan; 100(1):143-155. PubMed ID: 32488603
[TBL] [Abstract][Full Text] [Related]
12. Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions.
Cho HJ; Baek DW; Kim J; Lee JM; Moon JH; Sohn SK
Expert Rev Hematol; 2021 Sep; 14(9):819-830. PubMed ID: 34375536
[TBL] [Abstract][Full Text] [Related]
13. Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors-United States, July 2016-June 2019.
Gold JAW; Tolu SS; Chiller T; Benedict K; Jackson BR
Clin Infect Dis; 2022 Aug; 75(2):334-337. PubMed ID: 34893821
[TBL] [Abstract][Full Text] [Related]
14. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib dose modifications in the management of CLL.
Hardy-Abeloos C; Pinotti R; Gabrilove J
J Hematol Oncol; 2020 Jun; 13(1):66. PubMed ID: 32503582
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P;
Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597
[TBL] [Abstract][Full Text] [Related]
17. Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib.
Holowka T; Cheung H; Malinis M; Gan G; Deng Y; Perreault S; Isufi I; Azar MM
J Infect Chemother; 2021 Dec; 27(12):1700-1705. PubMed ID: 34389223
[TBL] [Abstract][Full Text] [Related]
18. [Disseminated cryptococcosis during ibrutinib treatment for chronic lymphocytic leukemia].
Kumekawa H; Watanabe D; Tamura K; Mizuchi D
Rinsho Ketsueki; 2022; 63(1):62-65. PubMed ID: 35135954
[TBL] [Abstract][Full Text] [Related]
19. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
Langerbeins P; Zhang C; Robrecht S; Cramer P; Fürstenau M; Al-Sawaf O; von Tresckow J; Fink AM; Kreuzer KA; Vehling-Kaiser U; Tausch E; Müller L; Eckart MJ; Schlag R; Freier W; Gaska T; Balser C; Reiser M; Stauch M; Wendtner CM; Fischer K; Stilgenbauer S; Eichhorst B; Hallek M
Blood; 2022 Jan; 139(2):177-187. PubMed ID: 34758069
[TBL] [Abstract][Full Text] [Related]
20. Screening and monitoring of the BTK
Bödör C; Kotmayer L; László T; Takács F; Barna G; Kiss R; Sebestyén E; Nagy T; Hegyi LL; Mikala G; Fekete S; Farkas P; Balogh A; Masszi T; Demeter J; Weisinger J; Alizadeh H; Kajtár B; Kohl Z; Szász R; Gergely L; Gurbity Pálfi T; Sulák A; Kollár B; Egyed M; Plander M; Rejtő L; Szerafin L; Ilonczai P; Tamáska P; Pettendi P; Lévai D; Schneider T; Sebestyén A; Csermely P; Matolcsy A; Mátrai Z; Alpár D
Br J Haematol; 2021 Jul; 194(2):355-364. PubMed ID: 34019713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
